摘要
目的比较扎来普隆治疗失眠症的有效性及安全性. 方法将96例失眠症患者随机分为研究组和对照组各48例,研究组予以扎来普隆5～10mg/d,对照组予以佐匹克隆7.5～15mg/d,两组疗程均为2周.采用睡眠障碍量表(SDRS)评定疗效,采用药物不良反应量表(TESS)评价不良反应.结果治疗结束时,两组SDRS评分均较治疗前显著减少(P<0.01).研究组有效率为83.3%,对照组为81.2%,两组比较差异无显著性意义(P>0.05).不良反应分析显示扎来普隆较常见不良反应为口干、头昏、口苦、恶心、头痛等,未出现严重不良反应.结论扎来普隆治疗失眠症安全有效.
Objective TO explore the efficacy and safety of zaleplon in the treatment of insomnia. Methods A total of 96 patients with insomnia were randomly assigned to receiving either zaleplon （5~10mg/d） （n=48） or zopicolone （7.5～15mg/d） （n=48） for 2 weeks. The clinical efficacy and side effects were evaluated with the Sleeping Dysfunction Rating Scale （SDRS） and Treatment Emergent Symptoms Scale （TESS）. Results Both groups showed significant improvement in the score of SDRS after treatment （P〈0.01）. The effective rates of zaleplon group and zopicolone group were 83. 30% and 81.2%, and there was no significant difference between two groups. The common adverse reactions in zaleplon group were dry mouth, dizziness, bitter taste, nausea and headache. Conclusion Zaleplon is effective and safe for treating insomnia.
出处
《山东精神医学》
2005年第4期254-255,共2页
Shangdong Archives of Psychiatry
